Goal Reached Thanks to every supporter — we hit 100%!

Goal: 1000 CNY · Raised: 1000 CNY

100.0%

CVE-2025-52654— HCL MyXalytics is affected by an HTML Injection

CVSS 4.6 · Medium EPSS 0.03% · P7
Get alerts for future matching vulnerabilitiesLog in to subscribe

I. Basic Information for CVE-2025-52654

Vulnerability Information

Have questions about the vulnerability? See if Shenlong's analysis helps!
View Shenlong Deep Dive ↗

Although we use advanced large model technology, its output may still contain inaccurate or outdated information.Shenlong tries to ensure data accuracy, but please verify and judge based on the actual situation.

Vulnerability Title
HCL MyXalytics is affected by an HTML Injection
Source: NVD (National Vulnerability Database)
Vulnerability Description
HCL MyXalytics v6.6 is affected by an HTML Injection. This issue occurs when untrusted input is included in the output without proper handling, potentially allowing unauthorized content injection and manipulation.
Source: NVD (National Vulnerability Database)
CVSS Information
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:L/I:L/A:N
Source: NVD (National Vulnerability Database)
Vulnerability Type
Web页面中脚本相关HTML标签转义处理不恰当(基本跨站脚本)
Source: NVD (National Vulnerability Database)
Vulnerability Title
HCL MyXalytics 安全漏洞
Source: CNNVD (China National Vulnerability Database)
Vulnerability Description
HCL MyXalytics是印度HCL公司的一款分析类软件产品。用于进行数据分析等相关工作。 HCL MyXalytics 6.6版本存在安全漏洞,该漏洞源于允许HTML注入,可能导致跨站脚本攻击。
Source: CNNVD (China National Vulnerability Database)
CVSS Information
N/A
Source: CNNVD (China National Vulnerability Database)
Vulnerability Type
N/A
Source: CNNVD (China National Vulnerability Database)

Affected Products

VendorProductAffected VersionsCPESubscribe
HCL SoftwareHCL MyXalytics 6.6 -

II. Public POCs for CVE-2025-52654

#POC DescriptionSource LinkShenlong Link
AI-Generated POCPremium

No public POC found.

Login to generate AI POC

III. Intelligence Information for CVE-2025-52654

登录查看更多情报信息。

IV. Related Vulnerabilities

V. Comments for CVE-2025-52654

No comments yet


Leave a comment